Pasithea Free Cash Flow Yield vs Price To Sales Ratio Analysis
| KTTAW Stock | USD 0.02 0 8.97% |
Pasithea Therapeutics financial indicator trend analysis is much more than just breaking down Pasithea Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pasithea Therapeutics is a good investment. Please check the relationship between Pasithea Therapeutics Free Cash Flow Yield and its Price To Sales Ratio accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pasithea Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Free Cash Flow Yield vs Price To Sales Ratio
Free Cash Flow Yield vs Price To Sales Ratio Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pasithea Therapeutics Free Cash Flow Yield account and Price To Sales Ratio. At this time, the significance of the direction appears to have totally related.
The correlation between Pasithea Therapeutics' Free Cash Flow Yield and Price To Sales Ratio is 0.99. Overlapping area represents the amount of variation of Free Cash Flow Yield that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of Pasithea Therapeutics Corp, assuming nothing else is changed. The correlation between historical values of Pasithea Therapeutics' Free Cash Flow Yield and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Yield of Pasithea Therapeutics Corp are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Free Cash Flow Yield i.e., Pasithea Therapeutics' Free Cash Flow Yield and Price To Sales Ratio go up and down completely randomly.
Correlation Coefficient | 0.99 |
| Relationship Direction | Positive |
| Relationship Strength | Very Strong |
Free Cash Flow Yield
A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.Price To Sales Ratio
Price to Sales Ratio is figured by comparing Pasithea Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Pasithea Therapeutics sales, a figure that is much harder to manipulate than other Pasithea Therapeutics Corp multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Most indicators from Pasithea Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pasithea Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pasithea Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. At this time, Pasithea Therapeutics' Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to climb to about 31 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 16.32 in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Other Operating Expenses | 4.5M | 15.3M | 16.0M | 9.9M | Depreciation And Amortization | 1.4K | 5.1K | 648.5K | 680.9K |
Pasithea Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Pasithea Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pasithea Stock Analysis
When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.